Le Lézard
Classified in: Health
Subjects: CHI, PDT

InventHelp Inventors Develop New Accessory for Sippy Cups (HAD-161)

PITTSBURGH, Aug. 9, 2022 /PRNewswire/ -- "Sippy cups are a breeding ground for the growth of mold and can cause children to get sick. With that in mind, we wanted to create a way to make cleaning sippy cups easier, and limit the amount of cleaning time," said one of two inventors, from Ft. Lauderdale, Fla., "so we invented SIPPY-SERTS. Our design eliminates the need to soak and scrub sippy cup interiors and it can help prevent the spread of germs."

The patent pending invention provides an effective way to keep the interior of a child's sippy cup clean. In doing so, it helps to prevent bacteria from building up in the valve lid liner. As a result, it enhances safety and it saves time and effort when cleaning sippy cups. The invention features a simple and eco-friendly design that is easy to apply, use and remove and it is ideal for parents who have children that utilize sippy cups. Additionally, it is disposable, BPA free, heavy duty, leak resistant, recyclable, microwave safe and producible in design variations.

The original design was submitted to the Ft. Lauderdale sales office of InventHelp. It is currently available for licensing or sale to manufacturers or marketers. For more information, write Dept. 20-HAD-161, InventHelp, 217 Ninth Street, Pittsburgh, PA 15222, or call (412) 288-1300 ext. 1368. Learn more about InventHelp's Invention Submission Services at http://www.InventHelp.com.

SOURCE InventHelp

These press releases may also interest you

at 00:29
Cadence Education, LLC. ("Cadence Education"), one of the largest providers of early childhood education in North America, announced that its 2022 annual company-wide fundraising St. Jude Trike-A-Thon event has raised $330,145. This brings Cadence...

at 00:00
This webinar will enable attendees to understand and comply with the FDA's cell and gene therapy...

30 nov 2022
IVERIC bio, Inc. (the "Company"), today announced the pricing of an upsized underwritten public offering of 13,350,000 shares of its common stock at a price to the public of $22.50 per share, less underwriting discounts and commissions. In addition,...

30 nov 2022
CNS Pharmaceuticals, Inc. ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the pricing of a public...

30 nov 2022
Aura Biosciences, Inc. ("Aura") , a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the pricing of an underwritten public offering of...

30 nov 2022
Liminatus Pharma LLC ("Liminatus"), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies and Iris Acquisition Corp ("Iris") , a publicly traded special purpose acquisition company ("SPAC") formed for the...

News published on 9 august 2022 at 12:15 and distributed by: